OptiNose presents data on highly effective nasal polyp treatment
(WFD Ventures) OptiNose today announced important results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis with nasal polyps. Patients experienced a significant reduction in polyp size and associated symptoms, with almost 80 percent reporting overall improvement. The data was presented at the annual meeting of the American Rhinologic Society....
9/20/2008 4:00:00 AM
EurekAlert! - Business and Economics
|
